{"symbol": "FATE", "companyName": "Fate Therapeutics Inc", "exchange": "NASDAQ", "industry": "Biological Product (except Diagnostic) Manufacturing ", "website": "www.fatetherapeutics.com", "description": "Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune\u2122, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.", "CEO": "John Wolchko", "securityName": "Fate Therapeutics Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2836, "employees": null, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Biological Product (except Diagnostic) Manufacturing "], "address": "3535 General Atomics Ct Ste 200", "address2": null, "state": "California", "city": "San Diego", "zip": "92121-1140", "country": "US", "phone": "18588751803"}